Skip to main content

NCBiotech News

  • BASF Plant Science researchers study stress-tolerant crops. Courtesy of BASF.
  • Charlotte-based merchant bank Bourne Partners, an adviser and investor in the Swiss specialty pharmaceutical company Covis Pharma, assisted in Covis’ acquisition of U.S. and Puerto Rico rights to GlaxoSmithKline drugs Fortaz, Zinacef, Lanoxin, Parnate and Zantac Injection. More
  • Five North Carolina scientists have stepped from the familiar surroundings of academic research into new environments in industry labs, thanks to a grant program established by the North Carolina Biotechnology Center. The five represent the 2011 class of Industrial Fellowship Program grant recipients in the program operated by the Center to provide real-world industry experience and to improve fellows’ competitive edge for high-level industrial research careers.
  • North Carolinians have until noon on Feb. 1 to submit preproposals to the North Carolina Biotechnology Center for the next round of Regional Development Grants. The grant program supports early-stage life-science economic development projects in communities statewide.  Two of the grants awarded by the Biotech Center in 2011 totaling $100,000 are boosting life-science economic development projects in the Research Triangle and Piedmont Triad regions.
  • A young biopharmaceutical company that moved its headquarters from Miami to Chapel Hill in 2011 has landed a $250,000 loan from the North Carolina Biotechnology Center. Heat Biologics, a clinical-stage immunotherapy company with a unique next-generation drug platform initially targeting cancer, received the maximum available from the Biotech Center’s Strategic Growth Loan program after an extensive review of the technical and commercial merits of the company’s R&D plans.
  • Reminder
  • Tengion, a global leader in the developing field of regenerative medicine, is officially calling Winston-Salem its home. The company, which is growing tissues and organs from recipients’ own cells in high-technology incubators, has had its R&D activities in North Carolina for seven years, but its corporate headquarters was in East Norriton, Pennsylvania.
  • A recently formed Research Triangle Park seed-stage investment fund has helped launch ophthalmic startup company Clearside Biomedical with $4 million in Series A venture financing.
  • A $30,000 loan from the North Carolina Biotechnology Center is helping NovaTarg grow in the Research Triangle Park area. NovaTarg, founded in Durham in 2009, is developing novel pharmaceutical products targeting liver diseases and diabetes.  The company received a $30,000 Company Inception Loan from the Biotech Center. The loan will help position it for raising outside funding that can advance its experimental therapies into clinical trials.
  • The North Carolina Biotechnology Center has awarded $1 million in grants to university scientists pursuing improved identification of prostate cancer, developing new membranes and mechanisms for improved drug therapies, and using genetics to improve swine health policy. Scientists at North Carolina State University, East Carolina University and the University of North Carolina Wilmington received the $250,000 Multidisciplinary Research Grants. Two of the grants went to NCSU.
  • Poinsettias -- white or red, mottled or green -- are the cheerful plant favored as the harbinger of these wintertime holidays.
  • Deadline: 2/8/12Agency: North Carolina Biotechnology CenterProgram: Collaborative Funding Grant (CFG)
  • If a link-up with a big corporation or venture fund is one of the business strategies you envision for your small company or developing product, you can sign up today to participate in a February partnering session in Raleigh with representatives from some major players. Companies such as Abbott, BASF, Bayer Crop Science, GlaxoSmithKline, LabCorp, Merck, Novartis, and United Therapeutics will have representatives available for the meetings.
  • Local, state and federal government leaders joined hundreds of employees at the massive Novartis vaccine manufacturing facility in Holly Springs this morning to celebrate the $1 billion factory’s first production of pandemic flu vaccine using the highly efficient process of cell culture.
  • When entrepreneur-turned-foundation CEO Max Wallace meets with someone seeking his organization’s money to develop a brain-cancer therapy, Wallace wants to hear a “pig at the breakfast table.” Chickens have a passive investment in the eggs on a breakfast plate, explained Wallace to audience laughter, but bacon or ham is far different. “That pig is really committed,” said Wallace. “And that’s who I want to see. I want to deal with the pig, not the chicken. Someone who’s got skin in the game.”
  • Triad BioNight 2012, an event to showcase the growth of the biotechnology sector throughout the Piedmont Triad, will be held Thursday, March 8, at the Sheraton Greensboro Hotel at Four Seasons. Robert (Bob) Ingram, general partner of Hatteras Venture Partners, will be the keynote speaker for the event. Hatteras is a Research Triangle Park-based venture capital firm with four funds and more than $200 million under management, including a new Hatteras Discovery fund focused on life science startups.
  • SoyMeds, a Davidson biotech research spin-out from the University of North Carolina Charlotte that is focused on the development and validation of soybean seed-based therapeutics to treat, prevent, cure, and diagnose disease, won the Life Sciences Company “21 Award” for 2011 from the North Carolina Technology Association. More
  • Three women from the North Carolina Biotechnology Center have been selected from among several thousand nominees as 2011 winners of Business Leader Media’s 10th Annual Women Extraordinaire Awards, which honor top women business leaders of the South.


Subscribe to News & Events